Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications - PubMed (original) (raw)

Review

Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications

Federico Pea. Clin Pharmacokinet. 2018 Feb.

Abstract

The intracellular pharmacokinetics of the different classes of antimicrobials into surrogate markers of tissue accumulation (alveolar macrophages and/or total alveolar cells collected by means of bronchoalveolar lavage or peripheral white blood cells) was reviewed. The aim of this review was to discuss the clinical implications of the intracellular pharmacokinetics of antibacterials, either from the therapeutic or toxicological perspective. The different pharmacokinetic behaviour of antimicrobials within cells is mainly related to their physicochemical properties (hydrophilicity and lipophilicity), and may have several clinical implications. Therapeutic efficacy against intracellular pathogens has been correlated mainly with the intracellular concentrations achieved by the different antimicrobial agents. This is relevant especially for macrolides, tetracyclines, fluoroquinolones and rifampicin in the treatment of bacterial infections such as Legionella pneumophila pneumonia, Mycoplasma pneumoniae pneumonia, non-gonococcal urethritis and chronic staphylococcal infections. Additionally, intracellular accumulation of antibacterials was correlated with the possibility of causing organ-specific toxicity, as in the case of aminoglycosides in regard to the risk of nephrotoxicity. Finally, it should be kept in mind that intracellular accumulation may also represent a drug reservoir in the case of lipophilic antimicrobials. This may become extremely relevant from the clinical standpoint when treating critically ill patients with sepsis with antibacterials. The pathophysiology of sepsis may explain why it is necessary to start therapy with an increased loading dose of hydrophilic antimicrobials to promptly achieve therapeutically effective concentrations.

PubMed Disclaimer

Similar articles

• [Tissue penetration of antibiotics. Does the treatment reach the target site?].
  Lagler H, Zeitlinger M. Lagler H, et al. Med Klin Intensivmed Notfmed. 2014 Apr;109(3):175-81. doi: 10.1007/s00063-013-0309-0. Epub 2014 Apr 2. Med Klin Intensivmed Notfmed. 2014. PMID: 24691884 Review. German.
• Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
  Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M. Mahmoudi L, et al. Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):285-91. Eur Rev Med Pharmacol Sci. 2013. PMID: 23426530 Clinical Trial.
• Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.
  Pea F, Viale P, Furlanut M. Pea F, et al. Clin Pharmacokinet. 2005;44(10):1009-34. doi: 10.2165/00003088-200544100-00002. Clin Pharmacokinet. 2005. PMID: 16176116 Review.
• The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents.
  Blot SI, Pea F, Lipman J. Blot SI, et al. Adv Drug Deliv Rev. 2014 Nov 20;77:3-11. doi: 10.1016/j.addr.2014.07.006. Epub 2014 Jul 15. Adv Drug Deliv Rev. 2014. PMID: 25038549 Review.
• Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
  Roberts JA, Lipman J. Roberts JA, et al. Clin Pharmacokinet. 2006;45(8):755-73. doi: 10.2165/00003088-200645080-00001. Clin Pharmacokinet. 2006. PMID: 16884316 Review.

Cited by

• Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA-approved targeted small molecule oncology drugs.
  Kotani N, Ito K. Kotani N, et al. Clin Transl Sci. 2023 Aug;16(8):1359-1368. doi: 10.1111/cts.13532. Epub 2023 May 12. Clin Transl Sci. 2023. PMID: 37173825 Free PMC article.
• Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients.
  van den Broek AK, Prins JM, Visser CE, van Hest RM. van den Broek AK, et al. BMC Infect Dis. 2021 Mar 20;21(1):285. doi: 10.1186/s12879-021-05919-w. BMC Infect Dis. 2021. PMID: 33743592 Free PMC article.
• Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.
  Zheng Y, Liu SP, Xu BP, Shi ZR, Wang K, Yang JB, Huang X, Tang BH, Chen XK, Shi HY, Zhou Y, Wu YE, Qi H, Jacqz-Aigrain E, Shen AD, Zhao W. Zheng Y, et al. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00686-18. doi: 10.1128/AAC.00686-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29941652 Free PMC article.
• Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation.
  Cao G, Zhu Y, Xie X, Chen Y, Yu J, Zhang J, Chen Z, Pang L, Zhang Y, Shi Y. Cao G, et al. Exp Ther Med. 2020 Jul;20(1):607-616. doi: 10.3892/etm.2020.8715. Epub 2020 May 5. Exp Ther Med. 2020. PMID: 32565928 Free PMC article.
• Chinese ICU physicians' knowledge of antibiotic pharmacokinetics/pharmacodynamics (PK/PD): a cross-sectional survey.
  Mao W, Lu D, Zhou J, Zhen J, Yan J, Li L; Zhejiang Provincial Critical Care Clinical Research Group. Mao W, et al. BMC Med Educ. 2022 Mar 14;22(1):173. doi: 10.1186/s12909-022-03234-9. BMC Med Educ. 2022. PMID: 35287666 Free PMC article.

References

1. 1. Crit Care Med. 2004 Aug;32(8):1678-82 - PubMed
2. 1. Antimicrob Agents Chemother. 2012 May;56(5):2627-34 - PubMed
3. 1. J Antimicrob Chemother. 2003 Jun;51(6):1431-4 - PubMed
4. 1. Antimicrob Agents Chemother. 2013 Apr;57(4):1736-42 - PubMed
5. 1. Antimicrob Agents Chemother. 2003 Aug;47(8):2450-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information